MetaCap

Capricor Therapeutics Inc. Company Profile

NASDAQ: CAPRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

7.59+0.06 (+0.80%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Capricor Therapeutics at a glance

Capricor Therapeutics Inc. (NASDAQ: CAPR) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in San Diego, CA. Capricor Therapeutics is led by Dr. Linda Marbán Ph.D. and employs about 231 people. At a market capitalization of $437.8 million, it is considered a small-cap company.

Its SEC Central Index Key (CIK) is 0001133869, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Capricor Therapeutics do?

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Business description based on the company's public filings.

Company information

Legal name
Capricor Therapeutics Inc.
Ticker
NASDAQ: CAPR
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Linda Marbán Ph.D.
Employees
231
Headquarters
10865 Road to the Cure, San Diego, CA, United States
Phone
858 727 1755
Market cap
$437.81M
SEC CIK
0001133869
Latest annual report
10-K · Mar 17, 2026

Companies similar to Capricor Therapeutics

CAPR peer companies
CompanyPrice% ChgMarket capCompare
AQSTAquestive Therapeutics Inc.3.46-6.61%$434.88Mvs CAPR
LYELLyell Immunopharma Inc.13.80+1.62%$441.82Mvs CAPR
INDPIndaptus Therapeutics Inc.2.82-9.90%$433.16Mvs CAPR
CTMXCytomX Therapeutics Inc.2.03-0.98%$442.55Mvs CAPR
EOLSEvolus Inc.6.52-6.86%$431.55Mvs CAPR
AMRNAmarin Corporation plc10.57-6.13%$444.39Mvs CAPR
DMACDiaMedica Therapeutics Inc.8.25+2.87%$445.15Mvs CAPR
KMDAKamada Ltd.7.74-1.15%$446.85Mvs CAPR

Related